Business Context and Reporting Period
Registrant: Landec Corporation (the filing metadata identifies Lifecore Biomedical, Inc., but the Form 10-Q is filed by Landec Corporation). The company operates through Food Products Technology, Food Export, and Hyaluronan-based Biomaterials businesses, including Lifecore Biomedical.
Period: Fiscal quarter ended August 25, 2013; comparable quarter ended August 26, 2012. Financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 FY2014 | Q1 FY2013 | Change |
|---|---|---|---|
| Total revenue | $109.5 million | $102.1 million | +7% |
| Gross profit | $12.5 million | $13.8 million | -9% |
| Gross margin | 11.4% | 13.5% | Down 210 bps |
| Operating income | $2.0 million | $3.0 million | -34% |
| Operating margin | 1.8% | 2.9% | Down 110 bps |
| Net income attributable to common stockholders | $4.8 million | $4.4 million | +9% |
| Diluted EPS | $0.18 | $0.17 | +6% |
| Operating cash flow | $4.5 million | $5.1 million | -11% |
Net income included $5.4 million of unrealized appreciation in the fair value of the Windset investment and $281,000 of dividend income. Excluding the fair-value gain, reported earnings would have been materially lower.
At August 25, 2013, cash and cash equivalents were $8.9 million, marketable securities were $1.3 million, and total current assets were $77.7 million versus current liabilities of $44.2 million. Total assets were $290.8 million and total equity was $185.5 million.
Debt included $38.9 million of long-term debt, including the current portion, and $1.1 million outstanding under Apio’s revolving line of credit. Lifecore had no borrowings under its $10.0 million revolving facility. Available borrowing capacity was $14.4 million under Apio’s revolver and $8.0 million under Lifecore’s revolver. The company reported compliance with all debt covenants.
Material Changes Versus the Prior Comparable Period
- Food Products Technology revenue increased 16% to $79.4 million, primarily from higher unit volumes, expanded product offerings, and new products.
- Food Export revenue declined 16% to $21.4 million because of Indonesian import quotas, lower unit volumes, and less favorable pricing and product mix.
- Hyaluronan-based Biomaterials revenue increased 8% to $8.6 million. Higher aseptic-filling revenue was partly offset by lower ophthalmic fermentation shipments caused by shipment timing.
- Gross profit declined despite higher revenue. Food Products Technology gross profit fell 11%, primarily because of lower-margin foodservice sales and approximately $2.0 million of adverse impact from raw produce sourcing costs associated with weather-related lower yields.
- Research and development expense decreased 13% to $1.9 million, while selling, general and administrative expense was broadly stable at $8.6 million.
- Cash declined by $4.8 million during the quarter. Operating cash flow of $4.5 million was more than offset by $4.1 million of investing outflows and $5.3 million of financing outflows.
- Capital expenditures increased to $4.3 million, principally for equipment supporting Apio and Lifecore growth.
- Interest expense declined 20% to $431,000, reflecting debt paydown since the prior-year first quarter.
Outlook, Risks, Contingencies, and Unusual Items
Management stated that existing cash, marketable securities, and operating cash flow should be sufficient to fund operational and capital requirements for at least the next twelve months. The filing provides no quantitative earnings or revenue guidance.
- Quarterly results may fluctuate because of seasonality in Apio’s food business and customer order timing at Lifecore.
- Weather, produce availability, sourcing costs, product mix, customer concentration, and foodservice pricing can materially affect margins.
- The five largest customers represented 44% of quarterly revenue; the two largest Food Products Technology customers represented 20% and 12% of revenue, respectively.
- The Windset investment was carried at $35.0 million and valued using Level 3 discounted cash flow assumptions. A 10% increase in discount rates or expense growth rates was estimated to reduce its value by approximately $1.5 million.
- Debt is secured by company and subsidiary assets and is subject to financial and operating covenants. Apio and Lifecore were in compliance at quarter-end.
- Related-party transactions included $580,000 of revenue and $1.9 million of product purchases during the quarter. These transactions were monitored and approved by the Audit Committee.
- The company reported approximately $1.0 million of unrecognized tax benefits and stated that it did not expect a significant change during the following twelve months.
- No material legal proceedings, defaults, or significant changes to previously disclosed risk factors were reported. Management concluded that disclosure controls were effective and that there were no material changes in internal control over financial reporting.
Investor Verification Checklist
- Verify the identity of the registrant: the supplied filing is Landec Corporation’s Form 10-Q, not a standalone Lifecore Biomedical filing.
- Assess recurring operating performance separately from the $5.4 million Windset fair-value gain.
- Monitor Food Products Technology margins and the effects of weather, produce costs, and foodservice mix.
- Review customer concentration and the timing of Lifecore’s fermentation and aseptic-filling shipments.
- Reconcile cash generation with $4.3 million of quarterly capital expenditures and scheduled debt amortization.
- Evaluate the sensitivity and liquidity of the $35.0 million Level 3 Windset investment.
- Confirm continued compliance with Apio and Lifecore debt covenants and availability under their revolving facilities.